VolitionRx Limited Share Price

Equities

VNRX

US9286611077

Biotechnology & Medical Research

Market Closed - Nyse 01:40:00 14/06/2024 am IST 5-day change 1st Jan Change
0.675 USD -2.54% Intraday chart for VolitionRx Limited -2.17% -5.86%
Sales 2024 * 28.55L 24Cr Sales 2025 * 1.35Cr 112.56Cr Capitalization 5.74Cr 479Cr
Net income 2024 * -3.2Cr -267.21Cr Net income 2025 * -2.2Cr -183.7Cr EV / Sales 2024 * 18.6 x
Net cash position 2024 * 44L 37Cr Net cash position 2025 * 2.59Cr 216.27Cr EV / Sales 2025 * 2.33 x
P/E ratio 2024 *
-1.85 x
P/E ratio 2025 *
-2.66 x
Employees 108
Yield 2024 *
-
Yield 2025 *
-
Free-Float 75.89%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.54%
1 week-2.17%
Current month-4.35%
1 month-23.08%
3 months-29.71%
6 months+22.73%
Current year-5.86%
More quotes
1 week
0.66
Extreme 0.66
0.74
1 month
0.66
Extreme 0.66
0.81
Current year
0.57
Extreme 0.57
1.23
1 year
0.55
Extreme 0.55
1.79
3 years
0.55
Extreme 0.55
4.14
5 years
0.55
Extreme 0.55
6.84
10 years
0.55
Extreme 0.55
9.28
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 06/11/06
Director of Finance/CFO 54 01/21/01
Chief Operating Officer 51 01/21/01
Members of the board TitleAgeSince
Chief Executive Officer 53 06/11/06
Chairman 80 06/11/06
Director/Board Member 67 06/11/06
More insiders
Date Price Change Volume
13/24/13 0.675 -2.54% 43,569
12/24/12 0.6926 -6.41% 87,611
11/24/11 0.74 +10.45% 39,555
10/24/10 0.67 -1.46% 68,107
07/24/07 0.6799 -1.46% 40,201

Delayed Quote Nyse, June 14, 2024 at 01:40 am IST

More quotes
VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.6926 USD
Average target price
3.467 USD
Spread / Average Target
+400.53%
Consensus